Respiratory Failure, Clinical Trial, Standard Care, Glucocorticoids, Covid, New England Journal Of Medicine, Tofacitinib

Respiratory Failure, Clinical Trial

Arthritis drug shows promise against severe Covid: study

A repurposed arthritis drug has shown positive results in a clinical trial of patients in Brazil hospitalised with COVID-19.

18/6/2021 4:30:00 AM

A repurposed arthritis drug has shown positive results in a clinical trial of patients in Brazil hospitalised with COVID-19.

A repurposed arthritis drug has shown positive results in a clinical trial of patients hospitalized with Covid -19, according to a paper published Wednesday in the New England Journal of Medicine.

Half received the drug -- a 10 mg pill twice a day -- and standard care like glucocorticoids that tamp down an overactive immune response, while the other half received a placebo and standard care.After 28 days, 18.1 percent of the group receiving the tofacitinib progressed to respiratory failure or death, compared to 29 percent in the placebo group.

Athletics: China's Su Bingtian makes 100m final, first Asian man in 89 years 113 new locally transmitted COVID-19 cases in Singapore, including 38 unlinked infections Olympics-Athletics-'Can we have two golds?' - Barshim, Tamberi share high jump win

This represented a statistically significant relative risk reduction of 63 percent.Respiratory failure refers to a patient requiring noninvasive ventilation through an oxygen mask, or being intubated and placed on a mechanical ventilator.Deaths after 28 days occurred in 2.8 percent of patients in the tofacitinib group and in 5.5 percent of those in the placebo group.

Serious side effects occurred in 14.1 percent in the tofacitinib group and in 12 percent in the placebo group."We are encouraged by the initial findings of our randomized trial of tofacitinib in patients hospitalized with COVID-19 pneumonia," said Otavio Berwanger of Hospital Israelita Albert Einstein, which coordinated the trial in collaboration with Pfizer. headtopics.com

"These results provide new information which indicates that the use of tofacitinib when added to standard of care, which includes glucocorticoids, may further reduce the risk of death or respiratory failure in this patient population."Tofacitinib belongs to a class of drugs called Janus kinase (JAK) inhibitors.

It is approved in the United States to treat conditions including rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. Read more: Yahoo Singapore »

At least 25 dead as rains deluge central China's Henan province

Pfizer's rheumatoid arthritis drug shows benefit in COVID-19 pneumoniaPfizer said on Wednesday (Jun 16) its oral rheumatoid arthritis drug Xeljanz reduced death or respiratory failure in hospitalised COVID-19 ...

Pfizer's rheumatoid arthritis drug shows benefit in Covid-19 pneumonia

19 new COVID-19 community cases in Singapore, including three unlinkedSINGAPORE: Singapore reported 19 new COVID-19 cases in the community as of noon on Wednesday (Jun 16), including three with no links to previous ... 哇,真么多?

19 community cases, including 3 unlinked, among 24 new Covid-19 infections in SingaporeSINGAPORE — Singapore reported 19 new Covid -19 community infections on Wednesday (June 16), three of which have not been traced to any previously reported cases.

India's famed Taj Mahal re-opens for tourists as Covid-19 curbs ease

Sydney records first local Covid-19 case in more than a month